Home » Stocks » Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc. (REXN)

Stock Price: $2.42 USD -0.05 (-2.02%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $2.63 +0.21 (8.68%) Aug 14, 5:44 PM

Stock Price Chart

Key Info

Market Cap 9.73M
Revenue (ttm) 1.15M
Net Income (ttm) -6.88M
Shares Out 4.23M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.42
Previous Close $2.47
Change ($) -0.05
Change (%) -2.02%
Day's Open 2.45
Day's Range 2.42 - 2.51
Day's Volume 12,056
52-Week Range 1.71 - 3.70

More Stats

Market Cap 9.73M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 4.23M
Float 3.80M
EPS (basic) -1.71
EPS (diluted) -2.66
FCF / Share -1.77
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14,514
Short Ratio 3.45
Short % of Float 2.54%
Beta 0.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.46
PB Ratio 1.09
Revenue 1.15M
Operating Income -7.84M
Net Income -6.88M
Free Cash Flow -7.12M
Net Cash 10.83M
Net Cash / Share 2.69
Gross Margin n/a
Operating Margin -681.74%
Profit Margin -598.20%
FCF Margin -619.54%
ROA -31.64%
ROE -54.20%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $2.42
Target: 3.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-11.22-20.54-17.35-16.41-18.26-13.27-7.98-6.58-16.13-10.31
Net Income-8.64-14.37-25.29-9.31-14.38-18.52-9.50-6.23-11.34-14.02
Shares Outstanding3.962.742.281.811.521.471.070.810.780.66
Earnings Per Share-2.18-5.25-11.04-5.16-9.48-13.20-8.40-7.20-14.40-21.60
Operating Cash Flow-10.28-18.84-15.42-13.23-17.35-11.04-7.98-6.62-15.53-6.99
Capital Expenditures-0.01-0.04-0.08-0.01-0.06-0.04-0.05--0.02-0.01
Free Cash Flow-10.29-18.88-15.50-13.24-17.41-11.08-8.04-6.62-15.55-6.99
Cash & Equivalents12.2214.7326.8320.3223.4432.7018.9814.6813.2415.19
Total Debt0.20---------
Net Cash / Debt12.0114.7326.8320.3223.4432.7018.9814.6813.2415.19
Book Value9.9610.5616.7717.0618.7826.5812.639.5310.7110.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rexahn Pharmaceuticals, Inc.
Country United States
Employees 5
CEO Douglas J. Swirsky

Stock Information

Ticker Symbol REXN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: REXN


Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.